Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent.

Exner, T; Favresse, J; Lessire, S; Douxfils, J; Mullier, F

Exner, T; Favresse, J; Lessire, S; Douxfils, J; Mullier, F.

Afiliação

Exner T; Haematex Research, Sydney, Australia. Electronic address: exner@optushome.com.au.
Favresse J; Université Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Institute for Life Sciences (NARILIS), Haematology Laboratory, Yvoir, Belgium.
Lessire S; Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Institute for Life Sciences (NARILIS), Department of Anesthesiology, Belgium.
Douxfils J; Université de Namur, NTHC/NARILIS, Department of Pharmacy, Belgium.
Mullier F; Université Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Institute for Life Sciences (NARILIS), Haematology Laboratory, Yvoir, Belgium.

Thromb Res ; 179: 69-72, 2019 Jul.

Article em En | MEDLINE | ID: mdl-31096112

Assuntos

Anticoagulantes/uso terapêutico; Coagulação Sanguínea/efeitos dos fármacos; Administração Oral; Anticoagulantes/farmacologia; Humanos

Palavras-chave

Activated partial thromboplastin time (aPTT); Apixaban; Correction Ratio; DOAC Stop™; DOACs; Dabigatran; Dilute Russells viper venom time (dRVVT); Rivaroxaban

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Coagulação Sanguínea / Anticoagulantes Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google